Meeder Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Meeder Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.39K	Sell	59 -70	-54%	-$4.9K	﹤0.01%	860
2026 Q1	$9.58K	Buy	129 +54	+72%	+$3.91K	﹤0.01%	704
2025 Q4	$5.74K	Hold	75	–	–	﹤0.01%	776
2025 Q3	$3.9K	Buy	75 +13	+21%	+$634	﹤0.01%	709
2025 Q2	$2.68K	Buy	+62	New	+$2.25K	﹤0.01%	791
2024 Q2	–	Sell	-82	Closed	-$2.54K	–	865
2024 Q1	$2.54K	Buy	+82	New	+$2.79K	﹤0.01%	705
2021 Q4	–	Sell	-2,034	Closed	-$95K	–	1272
2021 Q3	$95K	Buy	2,034 +649	+47%	+$34.8K	0.01%	908
2021 Q2	$84K	Sell	1,385 -1,630	-54%	-$93.1K	﹤0.01%	953
2021 Q1	$185K	Buy	+3,015	New	+$197K	0.01%	746
2020 Q4	–	Sell	-2,052	Closed	-$77K	–	1886
2020 Q3	$77K	Buy	2,052 +356	+21%	+$11.2K	0.01%	850
2020 Q2	$57K	Buy	1,696 +1,643	+3,100%	+$50K	﹤0.01%	896
2020 Q1	$2K	Buy	+53	New	+$1.64K	﹤0.01%	2058

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Meeder Asset Management's BBIO Position: Q2 2026 in Review

Meeder Asset Management reduced its BridgeBio Pharma (BBIO) stake by 54% in Q2 2026, selling an estimated $4.9K and leaving 59 shares worth $4.39K. The position accounts for ﹤0.01% of the portfolio, ranked #860.

Meeder Asset Management first reported a position in BBIO in Q1 2020 and has held it in 12 quarters since. The position peaked at $185K in Q1 2021. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Meeder Asset Management held 59 shares of BridgeBio Pharma worth $4.39K as of Q2 2026.
Meeder Asset Management sold 70 BridgeBio Pharma shares in Q2 2026, an estimated $4.9K.
BridgeBio Pharma made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #860 holding.
Meeder Asset Management first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 12 quarters since.
Meeder Asset Management's BridgeBio Pharma position peaked at $185K in Q1 2021.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.